Fortress Biotech (FBIO) vs Gossamer Bio (GOSS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Gossamer Bio (GOSS) over the past year, losing 26.6% versus a loss of 95.6%. Over five years, FBIO leads with a -95.5% price change compared with -98.7% for GOSS. Gossamer Bio is the larger company by market cap ($65.6 million vs $64.1 million), about 1.0 times the size, while Fortress Biotech is growing revenue faster (+9.7% vs -57.7%).
Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -351.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | GOSS |
|---|---|---|
| Share price | $1.90 | $10.72 |
| Market cap | $64.11M | $65.57M |
| 1-day change | +7.34% | -4.54% |
| YTD return | -48.09% | -95.68% |
| 1-year return | -26.64% | -95.62% |
| 5-year return | -95.52% | -98.74% |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-42.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | $48.47M |
| Revenue growth (YoY) | +9.69% | -57.74% |
| Net income (latest FY) | $6.82M | $-170.37M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | -352.23% |
| Net margin | 10.77% | -351.49% |
| 52-week high | $4.53 | $309.60 |
| 52-week low | $1.64 | $8.29 |
| Distance from 52-week high | -58.06% | -96.54% |
| Analyst consensus | none | buy |
| Avg. price target upside | +163.16% | +669.40% |
| Average volume | 281.49K | 243.40K |
| Shares outstanding | 33.74M | 6.12M |
| Employees | 78 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed GOSS by 69.0 percentage points over the past year.
- Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -351.5 cents for Gossamer Bio.
- Fortress Biotech grew revenue faster in its latest fiscal year (+9.69% vs -57.74%).
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
FBIO vs GOSS FAQ
Which is bigger, Fortress Biotech or Gossamer Bio?
Gossamer Bio (GOSS) is larger, with a market capitalization of $65.57M compared with $64.11M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or GOSS?
FBIO returned -26.64% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Gossamer Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.